Interstitial Lung Diseases: Clinical Features, Diagnosis, and Management
A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Medical Research".
Deadline for manuscript submissions: closed (30 September 2023) | Viewed by 1118
Special Issue Editors
Interests: idiopathic pulmonary fibrosis; interstitial lung disease; prognosis; progressive pulmonary fibrosis; rare interstitial lung disease
Special Issue Information
Dear Colleagues,
Interstitial lung diseases (ILDs) are chronic, parenchymal lung diseases with a variable clinical course and poor prognosis. The prevalence and incidence of ILD have been increasing. Accurate diagnosis is essential for better outcomes, but accurate diagnosis of ILD remains a major medical challenge due to the variability of clinical presentation and diagnostic uncertainty of current diagnostic tests. Multidisciplinary discussion (MDD) has been becoming the cornerstone of diagnosis of ILD, and the scope of MDD has expanded to monitoring disease progression comprising other specialists including cardiac surgeons, rheumatologists, and physiotherapists.
Within various clinical courses, acute exacerbation (AE) is a devastating condition with significant morbidity and high mortality. Additionally, progressive pulmonary fibrosis (PPF) implies the worsening of any preexisting ILD despite appropriate treatment and was recently defined in the ATS/ERS/JRS/ALAT guidelines. For better prognosis, early prediction and adequate treatment of AE and PPF are essential, even considering the limitations of real practice.
Two anti-fibrotic agents have been used worldwide and have significantly reduced lung function decline in patients with IPF. However, there are still many challenges to practical implementation such as the prediction of the treatment response, adequate methods of anti-fibrotic agents and other drugs, and the target disease of ILDs. Drugs other than anti-fibrotic agents and non-pharmacological treatment are also very important in patients with ILD.
This Special Issue will focus on the clinical features, diagnosis, and management of ILDs.
Dr. Jae Ha Lee
Dr. Hyun Kyung Lee
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- interstitial lung disease
- idiopathic pulmonary fibrosis
- diagnosis
- treatment
- prognosis
